Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

188.37 +3.36 (+1.81%)

Streaming Delayed Price Updated: 1:37 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

September 22, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...

Via FinancialNewsMedia

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 20, 2023

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

Via InvestorPlace

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

September 20, 2023

Via Investor Brand Network

Expert Ratings for Jazz Pharmaceuticals ↗

August 10, 2023

Via Benzinga

Where Jazz Pharmaceuticals Stands With Analysts ↗

July 11, 2023

Via Benzinga

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

September 20, 2023

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

Via FinancialNewsMedia

7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom ↗

September 19, 2023

Cannabis stocks re seeing renewed interest and these seven look like reasonable buys as rescheduling approaches for weed.

Via InvestorPlace

Topics Cannabis

Cannabis Industry Changes As Marijuana Rescheduling Looms ↗

September 15, 2023

As the Benzinga Cannabis Capital Conference returns to Chicago this Sept 27-28 for its 17th edition, gathering top CEOs, investors and leaders in the cannabis industry, let's scroll through the top...

Via Benzinga

Topics Cannabis

Is Axsome Therapeutics Stock a Screaming Buy? ↗

June 15, 2023

The biotech could be staring down an enormous commercial opportunity.

Via The Motley Fool

Expert Ratings for Jazz Pharmaceuticals ↗

June 05, 2023

Via Benzinga

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years ↗

September 12, 2023

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

Via Benzinga

Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030 ↗

August 26, 2023

These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel.

Via The Motley Fool

Topics Cannabis

Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO ↗

August 23, 2023

Verdemed, a pharmaceutical company known for producing cannabis-derived products, has received five fresh approvals from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância...

Via Benzinga

Topics Cannabis

Jazz Pharmaceuticals' Neuroscience Pipeline Readouts In Focus: Analyst Lowers Price Target ↗

August 14, 2023

Cantor Fitzgerald analyst Charles C.

Via Benzinga

Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues? ↗

August 09, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year.

Via Benzinga

Cannabis Stock Gainers And Losers From August 11, 2023 ↗

August 11, 2023

Via Benzinga

Topics Cannabis

3 Biotech Stocks You’ll Regret Not Buying Soon ↗

August 08, 2023

These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 08, 2023

Via Benzinga

GOP Rep. Blasts FDA Over CBD Inaction During Historic Hearing: The Agency Wants More Money To Do Its Job ↗

July 28, 2023

For the first time, Congress officially addressed the impact of the U.S. Food and Drug Administration’s (FDA) inaction regarding the regulations of CBD products.

Via Benzinga

FDA, Get It Done! Says Senator In Bipartisan Push To Regulate CBD Products Prior To Committee Hearing ↗

July 21, 2023

A bipartisan group of U.S. lawmakers reintroduceda measure on Wednesdaythat aims to secure theFood and Drug ...

Via Benzinga

Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group ↗

July 10, 2023

Is the battle for medical marijuana legalization in North Carolina over for this year? Some groups say yes, some say know, here is what happened.

Via Benzinga

4 Unequaled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

July 08, 2023

Bargains are hiding in plain sight with the Nasdaq Composite still well below its November 2021 record-closing high.

Via The Motley Fool

Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful' ↗

June 23, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive day

Via Benzinga

10 Cannabis Stocks That Could Go Sky High In 2023 ↗

June 18, 2023

With cannabis legalization gaining momentum, investing in cannabis presents a lucrative opportunity. Investors may want to explore cannabis stocks to enhance their portfolios. Here are the top 10...

Via Talk Markets

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

Stocks That Hit 52-Week Lows On Tuesday ↗

June 13, 2023

On Tuesday, 32 companies reached new 52-week lows.

Via Benzinga

3 Cheap Growth Stocks That Are Too Good to Pass Up ↗

June 05, 2023

These top bargain growth stocks are all priced under $10 a share and offer real upside potential for investors.

Via InvestorPlace

Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

May 31, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END

Via FinancialNewsMedia

FDA Presents Potential Framework For CBD, From Edibles To Delta-8, Reaffirms Congress Is In Charge ↗

May 30, 2023

The U.S. Food and Drug Administration has not given up on regulating CBD and hemp-derived products in a way that would be safe for consumers and producers.

Via Benzinga

Ford To Rally Around 33%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

May 30, 2023

Keybanc boosted the price target for Broadcom Inc. (NASDAQ: AVGO) from $720 to $820. Keybanc analyst John Vinh maintained the stock with an Overweight rating. Broadcom shares rose 11.5% to close at...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.